While the coordinated timing among C-suite executives is notable, the dollar amount is not material relative to company size and is consistent with routine portfolio management. Traders should monitor for follow-up filings; absence of further large sales suggests this may not signal negative outlook.
APGE drugs
APGE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $84.24entry
- T+1 · 8mo ago +0.12%α +0.04% · $84.34
- T+5 · 7mo ago +2.71%α −1.06% · $86.52
- T+20 · 7mo ago −2.62%α −12.35% · $82.03
- T+60 · 5mo ago +57.42%α +44.04% · $132.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three corporate insiders at Apogee Therapeutics, including the CEO, CFO, and CMO, sold shares totaling $1.77 million over a 7-day period, with the majority of the activity coming from CEO Michael Thomas Henderson's $1.47 million open-market sale. This represents coordinated selling by top executives, though the total value remains below 0.1% of the company's $6.0B market cap.
Key Financial Metrics
Key Facts
- Insider cluster involves three C-suite executives: CEO, CFO, and CMO.
- Total value of sales: $1.77 million, all via open-market transactions (S).
- CEO Michael Thomas Henderson sold $1.47 million of shares, accounting for 83% of the total cluster value.
- Sales occurred between 2026-04-01 and 2026-04-08, indicating concentrated timing.
- Total insider selling represents approximately 0.03% of Apogee Therapeutics' $6.0B market capitalization.
Financial Impact
Total insider sales amount to $1.77M, or 0.03% of market cap, below the 0.1% threshold for materiality.
Risk Factors
- Perception risk: Concentrated selling by top executives could be interpreted negatively by retail investors.
- Timing risk: Clustered sales around potential news events (e.g., upcoming earnings or clinical data) could imply information asymmetry.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-APGE-1775865642863 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers